Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RT-IMMUNE atezolizumab trial in localized operable soft tissue sarcoma
2024-510713-15-00Phase 2Authorised
- Sponsor
- Centre Léon Bérard
- Start
- Jul 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of atezolizumab in soft tissue sarcoma (STS) (2 arms), sponsored by Centre Léon Bérard. Primary endpoint: Pathological response rate. Planned start Jul 2018; status: authorised.
02
Drugs
atezolizumab
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on 2024-510713-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-510713-15-00.